Nanomedicine approaches for in vivo cancer immunotherapy

References

• 1. Petersen GH, Alzghari SK, Chee W, Sankari SS, La-Beck NM. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Rel. 232, 255–264 (2016).
  Medline CASGoogle Scholar
• 2. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJMM, Lammers T. Smart cancer nanomedicine. Nat. Nanotechnol. 14(11), 1007–1017 (2019).
  MedlineGoogle Scholar
• 3. Martin JD, Cabral H, Stylianopoulos T et al. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17, 251–266 (2020).
  MedlineGoogle Scholar
• 4. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18(3), 175–196 (2019).
  Medline CASGoogle Scholar
• 5. Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40(6), 840–854 (2022).
  Medline CASGoogle Scholar
• 6. Kulkarni JA, Witzigmann D, Thomson SB et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16(6), 630–643 (2021).
  Medline CASGoogle Scholar
• 7. Liu C, Shi Q, Huang X et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).
  MedlineGoogle Scholar
• 8. Deckers J, Anbergen T, Hokke AM et al. Engineering cytokine therapeutics. Nat. Rev. Bioeng. 2023, 1–18 (2023).
  Google Scholar
• 9. Hewitt SL, Bai A, Bailey D et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci. Transl. Med. 11(477), eaat9143 (2019).
  Medline CASGoogle Scholar
• 10. Zhang Y, Hou X, Du S et al. Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy. Nat. Nanotechnol. https://doi.org/10.1038/s41565-023-01453-9 (2023).
  Google Scholar
• 11. Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21(4), 1–22 (2022).
  MedlineGoogle Scholar
• 12. Dolgin E. Personalized cancer vaccines pass first major clinical test. Nat. Rev. Drug Discov. 22(8), 607–609 (2023).
  Medline CASGoogle Scholar
• 13. Rojas LA, Sethna Z, Soares KC et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
  Medline CASGoogle Scholar
• 14. Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat. Med. 2023 https://doi.org/10.1038/d41591-023-00072-0 (2023).
  Google Scholar
• 15. Netea MG, Joosten LABB, Latz E et al. Trained immunity: a program of innate immune memory in health and disease. Science 352(6284), 427 (2016).
  CASGoogle Scholar
• 16. van Leent MMT, Priem B, Schrijver DP et al. Regulating trained immunity with nanomedicine. Nat. Rev. Mater. 7(6), 465–481 (2022).
  Google Scholar
• 17. Kalafati L, Kourtzelis I, Schulte-Schrepping J et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183(3), 771–785.e12 (2020).
  Medline CASGoogle Scholar
• 18. Geller AE, Shrestha R, Woeste MR et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat. Commun. 13(1), 1–20 (2022).
  MedlineGoogle Scholar
• 19. Ding C, Shrestha R, Zhu X et al. Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis. Nat. Immunol. 24(2), 239–254 (2023).
  Medline CASGoogle Scholar
• 20. Priem B, van Leent MMT, Teunissen AJP et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183(3), 786–801.e19 (2020).
  Medline CASGoogle Scholar
• 21. Rosenblum D, Gutkin A, Kedmi R et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6(47), eabc9450 (2020).
  Medline CASGoogle Scholar
• 22. Rurik JG, Tombácz I, Yadegari A et al. CAR T cells produced in vivo to treat cardiac injury. Science 375(6576), 91–96 (2022).
  Medline CASGoogle Scholar
• 23. Segel M, Lash B, Song J et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373(6557), 882–889 (2021).
  Medline CASGoogle Scholar